Effects of aspartame on hsp70, bcl-2 and bax expression in immune organs of Wistar albino rats

Abstract

Aspartame, a ‘first generation sweetener’, is widely used in a variety of foods, beverages, and medicine. The FDA has determined the acceptable daily intake (ADI) value of aspartame to be 50 mg/kg of body weight/day, while the JECFA (Joint FAO/WHO Expert Committee on Food Additives) has set this value at 40 mg/kg of body weight/day. Safety issues have been raised about aspartame due to its metabolites, specifically toxicity from methanol and/or its systemic metabolites formaldehyde and formic acid. The immune system is now recognized as a target organ for many xenobiotics, such as drugs and chemicals, which are able to trigger unwanted apoptosis or to alter the regulation of apoptosis. Our previous studies has shown that oral administration of aspartame (40 mg/kg.bw/day) or its metabolites for 90 days increased oxidative stress in immune organs of Wistar albino rats. In this present study, we aimed to clarify whether aspartame consumption over a longer period (90-days) has any effect on the expression of hsp70, bcl-2 and bax at both mRNA transcript and protein expression levels in immune organs. We observed that oral administration of aspartame for 90 days did not cause any apparent DNA fragmentation in immune organs of aspartame treated animals; however, there was a significant increase in hsp70 expression, apart from significant alteration in bcl-2 and bax at both mRNA transcript and protein expression level in the immune organs of aspartame treated animals compared to controls. Hence, the results indicated that hsp70 levels increased in response to oxidative injury induced by aspartame metabolites; however, these metabolites did not induce apoptosis in the immune organs. Furthermore, detailed analyses are needed to elucidate the precise molecular mechanisms involved in these changes.

Keywords

aspartame / immune organs / hsp70 / bcl2 / bax

References

[1] Hertelendy ZI, Mendenhall CL, Rouster SD, Biochemical and clinical effects of aspartame in patients with chronic, stable alcoholic liver disease[J]. Am J Gastroenterol, 1993, 88(5): 737–743

[2] Pohannish RP. Sittig’s handbook of toxic and hazardous chemicals and carcinogens, Noyes/William Andrew, Norwich, NY 2002.

[3] Tang X, Bai Y, Duong A, Formaldehyde in China: production, consumption, exposure levels, and health effects[J]. Environ Int, 2009, 35(8): 1210–1224

[4] European Food Safety Authority (EFSA). Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with Food (AFC) on a request from the Commission related to a new long-term carcinogenicity study on aspartame[J]. EFSA J, 2006, 356: 1–44.

[5] Kotsonis FN, Hjelle JJ. The safety assessment of aspartame:Scientific and regulatory considerations[A], In: Tschanz, C, Butchko HH, Stargel WW. Kotsonis FN (eds), The Clinical Evaluation of a Food Aditive Assessment of Aspartame[M]. CRC Press, Boca Raton FL, 1996; 23–41.

[6] Stegink LD, Filer LJ Jr, Baker GL. Repeated ingestion of aspartame-sweetened beverage: effect on plasma amino acid concentrations in normal adults[J]. Metabolism, 1988, 37(3): 246–251

[7] Chew BP, Park JS. Carotenoids Against Disease: Part C: The Immune System and Disease[A]. In: Britton G, Liaanen-Jensen S, Pfander H 9 (eds) Carotenoids: Nutrition and Health[M]. 2009, Germany: Birkhauser Press, 5: 363–382.

[8] Tortorella D, Gewurz BE, Furman MH, Viral subversion of the immune system[J]. Annu Rev Immunol, 2000, 18(1): 861–926

[9] Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells[J]. Annu Rev Immunol, 2004, 22: 891–928

[10] Ogi S, Tanji N, Iseda T, Expression of heat shock proteins in developing and degenerating rat testes[J]. Arch Androl, 1999, 43(3): 163–171

[11] Kültz D. Molecular and evolutionary basis of the cellular stress response[J]. Annu Rev Physiol, 2005, 67: 225–257

[12] DeBiasi RL, Robinson BA, Leser JS, Critical role for death-receptor mediated apoptotic signaling in viral myocarditis[J]. J Card Fail, 2010, 16(11): 901–910

[13] Cheng WC, Leach KM, Hardwick JM. Mitochondrial death pathways in yeast and mammalian cells[J]. Biochim Biophys Acta, 2008, 1783(7): 1272–1279

[14] Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family[J]. Trends Biochem Sci, 2001, 26(1): 61–66

[15] Win-Shwe TT, Yoshida Y, Kunugita N, Does early life toluene exposure alter the expression of NMDA receptor subunits and signal transduction pathway in infant mouse hippocampus[J]? Neurotoxicology, 2010, 31(6): 647–653

[16] Choudhary AK, Devi RS. Imbalance of the oxidant-antioxidant status by aspartame in the organs of immune system of Wistar albino rats[J]. Afr J Pharm Pharmacol, 2014, 8: 220–230.

[17] Choudhary AK, Sheela Devi R. Longer period of oral administration of aspartame on cytokine response in Wistar albino rats[J]. Endocrinol Nutr, 2015, 62(3): 114–122

[18] Choudhary AK, Rathinasamy SD. Aspartame induces alteration in electrolytes homeostasis of immune organs in wistar albino rats[J]. Biomedicine and Preventive Nutrition, 2014, 4: 181–187.

[19] Choudhary AK, Rathinasamy SD. Effect of long intake of aspartame on ionic imbalance in immune organs of immunized wistar albino rats[J]. Biomedicine and Aging Pathology, 2014, 4: 243–249.

[20] Gombos K, Varjas T, Orsós Z, The effect of aspartame administration on oncogene and suppressor gene expressions[J]. In Vivo, 2007, 21(1): 89–92

[21] Makar AB, Tephly TR. Methanol poisoning in the folate-deficient rat[J]. Nature, 1976, 261(5562): 715–716

[22] Ming H, Wang SY, Craig A. Meadows, Shirley W. Thenen Methotrexate effects on folate status and the deoxyuridine suppression test in rats[J]. Nut Res, 1989, 9: 431–444.

[23] Rabinowitz JC, Pricer WE. Formiminotetrahydrofolic acid and methenyltetrahydrofolic acid as intermediates in the formation of N10-formyltetrahydrofolic acid[J]. J Am Chem Soc, 1956, 78(21): 5702–5704.

[24] Feldman S, Conforti N. Participation of the dorsal hippocampus in the glucocorticoid feedback effect on adrenocortical activity[J]. Neuroendocrinology, 1980, 30(1): 52–55

[25] Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction[J]. Anal Biochem, 1987, 162(1): 156–159

[26] Pockley AG. Heat shock proteins as regulators of the immune response[J]. Lancet, 2003, 362(9382): 469–476

[27] Sun L, Chang J, Kirchhoff SR, Activation of HSF and selective increase in heat-shock proteins by acute dexamethasone treatment[J]. Am J Physiol Heart Circ Physiol, 2000, 278(4): H1091–H1097

[28] Beere HM, Green DR. Stress management- heat shock protein-70 and the regulation of apoptosis[J]. Trends Cell Biol, 2001, 11(1): 6–10

[29] Robertson JD, Orrenius S. Molecular mechanisms of apoptosis induced by cytotoxic chemicals[J]. Crit Rev Toxicol, 2000, 30(5): 609–627

[30] Hunot S, Flavell RA. Apoptosis. Death of a monopoly[J]? Science, 2001, 292(5518): 865–866

[31] Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization[J]? Trends Cell Biol, 2008, 18(4): 157–164

[32] Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer[J]. Carcinogenesis, 2005, 26(2): 263–270

Acknowledgments

The authors gratefully acknowledge the University of Madras for their financial support. [UGC No.D.1. (C)/TE/2012/1868.The authors acknowledge Mr. Sunderaswaran Loganathan for his constant support and help.

RIGHTS & PERMISSIONS

2016 2016 by the Journal of Biomedical Research. All rights reserved